Rybelsus (Being Discontinued in the US) vs Trulicity: Daily Tablet or Weekly Shot
Rybelsus (semaglutide (oral), Novo Nordisk) vs Trulicity (dulaglutide, Eli Lilly)
Last verified November 2026
The verdict
Both are diabetes drugs, neither is approved for weight management, and the weight figures (−3.7 kg on Rybelsus 14 mg at 26 weeks in PIONEER 1, −2 to −3 kg on Trulicity) come from diabetes programs rather than obesity trials. Rybelsus needs the fasting window that oral semaglutide absorption requires; Trulicity is one weekly injection with no food rules. Each has an outcomes trial showing fewer major cardiac events: REWIND for dulaglutide and SOUL for oral semaglutide (HR 0.86). In the US, Rybelsus is being discontinued and replaced by Ozempic tablets, which cost $149–$299 a month self-pay. For most people the formulary makes this decision.
Side-by-side comparison
| Field | Rybelsus | Trulicity |
|---|---|---|
| How you take it | A tablet each morning on an empty stomach | An injection under the skin, once a week |
| How it works | Semaglutide, a GLP-1 receptor agonist, paired with an absorption enhancer so a fraction survives the stomach | Dulaglutide, a GLP-1 receptor agonist fused to an antibody fragment so it lasts a week |
| Blood-sugar reduction on its own | -0.9% to -1.4% over 26 weeks at 14 mg (PIONEER 1) | -1.1% to -1.4% over 26 to 52 weeks at 1.5 mg (AWARD program) |
| Weight lost at the top dose, in diabetes | -3.7 kg over 26 weeks at 14 mg (PIONEER 1; placebo -1.4 kg) | -2 to -3 kg over 26 to 52 weeks at 1.5 mg (AWARD program) |
| Whether food gets in the way | Empty stomach, no more than 4 oz of plain water, then nothing for 30 minutes | Nothing to plan around — any time of day, with or without food |
| Whether a trial proved it prevents heart attacks and strokes | SOUL cut major cardiac events 14% (HR 0.86) at 14 mg, in a trial built to test that. PIONEER 6 had shown it was not worse than placebo | REWIND cut major cardiac events 12%, in a trial built to test exactly that |
| Youngest approved age | Adults only, with no pediatric label | 10 and over, for type 2 diabetes |
| What it costs if you pay cash | $149–$299/mo self-pay as Ozempic tablets, its US replacement | $389/mo via LillyDirect self-pay; list about $1,007 for a month's carton of four pens |
What each one costs in the compounded market
Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.
Rybelsus — semaglutide (oral)
from $47 /mo
463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.
Where to get semaglutide — a selection of sellers, not a price ranking
- Embody review$79/mo
- SnagRx review$99/mo
- Collective review$59/mo + membership
Trulicity — dulaglutide
No seller on this register publishes a compounded price for it. For a drug still in trials that is expected — and anyone selling it anyway is doing so outside the system this register covers.
⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.
Frequently asked questions
Are Rybelsus and Trulicity the same drug?
No. Rybelsus is semaglutide (oral) and Trulicity is dulaglutide — different molecules. Results with one do not predict results with the other.
Is Rybelsus or Trulicity cheaper?
On the manufacturers' own cash pricing: Rybelsus at $149–$299/mo self-pay as Ozempic tablets, its US replacement, Trulicity at $389/mo via LillyDirect self-pay; list about $1,007 for a month's carton of four pens. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.
What does a compounded version of each actually cost?
Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide (oral) from $47 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.
Can I switch from Rybelsus to Trulicity?
Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.
Which one should I ask for?
That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.
References
- 1.Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31186300.
- 2.Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019. PMID: 31186120.
- 3.Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511.
- 4.Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018. PMID: 29910024.
- 5.Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med. 2019. PMID: 31185157.
- 6.Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets — Prescribing Information (revised January 2026). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- 7.Eli Lilly and Company. TRULICITY (dulaglutide) injection — Prescribing Information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
- 8.McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. 2025. PMID: 40162642.
- 9.Novo Nordisk. Ozempic (semaglutide) pill available in the US starting May 4 (press release, May 1, 2026). Novo Nordisk US newsroom. 2026. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916540
Related comparisons
- Rybelsus vs Zepbound
- Rybelsus vs Mounjaro
- Foundayo vs Trulicity
- Saxenda vs Trulicity
- Wegovy vs Rybelsus
- Zepbound vs Trulicity
See the full drug-vs-drug verdict index or provider rankings.